Comparing two drugs for myelofibrosis with low blood counts
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary myelofibrosis, or myelofibrosis that started after polycythemia vera or essential thrombocythemia, confirmed by a bone marrow biopsy within the last 4 years.
- Your spleen is at least 450 cm³ in size (about the size of a large grapefruit) as measured by MRI or CT scan.
- You have not had any prior treatment for myelofibrosis with JAK inhibitors (such as ruxolitinib or fedratinib) or ACVR1 inhibitors.
- You are not eligible for or have not had a stem cell transplant for myelofibrosis.
- You must be able to take pills by mouth and have adequate kidney function (creatinine clearance of 30 mL/min or more).
- You must not have had your spleen removed or received radiation to the spleen in the past 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a combination of two drugs, selinexor and pacritinib, for people with myelofibrosis who have not had previous JAK inhibitor treatment and have low red blood cells (anemia) or low platelets. The goal is to see if these drugs can help improve symptoms and reduce spleen size while being safe for patients with cytopenias.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial is studying the effectiveness of momelotinib, a JAK inhibitor, for people with myelofibrosis who have an enlarged spleen. It aims to see how well the drug works in real-world practice.
This trial tests a new combination of two drugs, bomedemstat and momelotinib, for people with myelofibrosis. It aims to see if adding bomedemstat can help when momelotinib alone isn't working well enough, or for those with low blood counts.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.